We are very happy to share our latest review paper! The power of personalized immunotherapy is becoming more and more apparent. The data presented at the AACR Annual meeting and the Neoantigen Summit this spring is exciting and showcases the momentum neoantigen-directed therapeutics are in.

The review provides an in-depth overview of the current state of the field with an emphasis on in silico neoantigen discovery and the clinical aspects that need to be addressed to unlock the full potential of this therapy.

A fundamental prerequisite for the efficacy of cancer immunotherapy is the presence of functional, antigen-specific T cells within the tumor. Neoantigen-directed therapy is a promising strategy that aims at targeting the host’s immune response against tumor-specific antigens, thereby eradicating cancer cells. Initial forays have been made in clinical environments utilizing vaccines and adoptive cell therapy; however, many challenges lie ahead.